EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic targeting of PLK1 in TERT promoter‐mutant hepatocellular carcinoma

Qin Tang, Guanghui Hu, Ye Sang, Yulu Chen, Guangyan Wei, Meiyan Zhu, Mengke Chen, Shiyong Li, Rengyun Liu iD, Zhenwei Peng iD

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.1703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Qin Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Telomerase, Carcinoma, Hepatocellular, Liver Neoplasms, Polo-Like Kinase 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Talents Program of The First Affiliated Hospital of Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hotspot mutations in the promoter of telomerase reverse transcriptase ( TERT ) gene are the most common genetic variants in hepatocellular carcinoma (HCC) and associated with poor prognosis of the disease. However, no drug was currently approved for treating TERT promoter mutation positive HCC patients. Here, we aim to explore the potential therapeutic strategy for targeting TERT promoter mutation in HCC.

Methods

The Liver Cancer Model Repository database was used for screening potential drugs to selectively suppress the growth of TERT promoter mutant HCC cells. RNA‐seq, CRISPR‐Cas9 technology and siRNA transfection were performed for mechanistic studies. Cell counting kit‐8 (CCK8) assay and the xenograft tumour models were used for cell growth detection in vitro and in vivo, respectively. Cell apoptosis and cell cycle arrest were analysed by Annexin V‐FITC staining and/or propidium iodide staining.

Results

PLK1 inhibitors were remarkably more sensitive to HCC cells harbouring TERT promoter mutation than wild‐type cells in vitro and in vivo, which were diminished after TERT promoter mutation was edited to the wild‐type nucleotide. Comparing the HCC cells with wild‐type promoter of TERT , PLK1 inhibitors specifically downregulated Smad3 to regulate TERT for inducing apoptosis and G2/M arrest in TERT mutant HCC cells. Moreover, knockout of Smad3 counteracted the effects of PLK1 inhibitors in TERT mutant HCC cells. Finally, a cooperative effect of PLK1 and Smad3 inhibition was observed in TERT mutant cells.

Conclusions

PLK1 inhibition selectively suppressed the growth of TERT mutant HCC cells through Smad3, thus contributed to discover a novel therapeutic strategy to treat HCC patients harbouring TERT promoter mutations. Key points TERT promoter mutation confers sensitivity to PLK1 inhibitors in HCC. The selective growth inhibition of TERT mutant HCC cells induced by PLK1 inhibitor was mediated by Smad3. Combined inhibition of PLK1 and Smad3 showed a cooperative anti‐tumor effect in TERT mutant HCC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseCarcinoma, HepatocellularLiver NeoplasmsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsCell Cycle ProteinsPromoter Regions, GeneticHumansAnimalsMutationMiceCell Line, TumorApoptosis

Stichwörter der Autor:innen

PLK1Smad3TERT promoter mutationhepatocellular carcinoma

Substanzen

TelomerasePolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsCell Cycle ProteinsTERT protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Rengyun Liu, Zhenwei Peng

Förderung

  • National Natural Science Foundation of China
  • Research Talents Program of The First Affiliated Hospital of Sun Yat-sen University

Zitieren

APA

Tang, Q., Hu, G., Sang, Y., Chen, Y., Wei, G., Zhu, M., Chen, M., Li, S., Liu, R., & Peng, Z. (2024). Therapeutic targeting of PLK1 in TERT promoter‐mutant hepatocellular carcinoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1703

Vancouver

Tang Q, Hu G, Sang Y, Chen Y, Wei G, Zhu M, et al. Therapeutic targeting of PLK1 in TERT promoter‐mutant hepatocellular carcinoma. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1703

BibTeX
@article{Tang2024,
  author = {Tang, Qin and Hu, Guanghui and Sang, Ye and Chen, Yulu and Wei, Guangyan and Zhu, Meiyan and Chen, Mengke and Li, Shiyong and Liu, Rengyun and Peng, Zhenwei},
  title = {Therapeutic targeting of PLK1 in TERT promoter‐mutant hepatocellular carcinoma},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.1703}
}
Kostenlos starten →